Last reviewed · How we verify
SCT510A
SCT510A is a genetically modified allogeneic natural killer cell therapy designed to enhance anti-tumor immunity.
SCT510A is a genetically modified allogeneic natural killer cell therapy designed to enhance anti-tumor immunity. Used for Hematologic malignancies (under investigation in Phase 3).
At a glance
| Generic name | SCT510A |
|---|---|
| Sponsor | Sinocelltech Ltd. |
| Drug class | Natural killer cell therapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SCT510A consists of engineered natural killer (NK) cells derived from healthy donors that have been modified to improve their ability to recognize and kill cancer cells. The therapy leverages NK cell cytotoxicity while potentially incorporating genetic modifications to enhance persistence, activation, and tumor-targeting capabilities. As an off-the-shelf cellular immunotherapy, it aims to provide a readily available treatment option for cancer patients.
Approved indications
- Hematologic malignancies (under investigation in Phase 3)
Common side effects
- Cytokine release syndrome
- Infusion-related reactions
- Hematologic toxicity
Key clinical trials
- This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD (PHASE3)
- The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCT510A CI brief — competitive landscape report
- SCT510A updates RSS · CI watch RSS
- Sinocelltech Ltd. portfolio CI